ads_id stringlengths 8 8 | arxiv_id int64 0 999 | title stringlengths 0 236 | abstract stringlengths 0 4.26k ⌀ | embed sequencelengths 1.54k 1.54k | date date32 | cites int64 1 1.16k | bibcode stringlengths 8 8 | keywords sequencelengths 0 30 | ads_keywords sequencelengths 0 14 | read_count int64 0 0 | doi stringlengths 13 16.8k ⌀ | authors sequencelengths 0 66 | aff sequencelengths 0 66 | cite_bibcodes sequencelengths 1 1.16k | ref_bibcodes sequencelengths 0 0 | umap_x float32 4.76 33.7 | umap_y float32 2.73 7.65 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
39844819 | 0 | Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies. | In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made groundbreaking progress in the treatment of various cancer types, particularly hematological malignancies. In the meantime, various preclinical and clinical studies have extensively explored dual-target CAR-T therapies which can be designed to r... | [
0.021476397290825844,
-0.012967296876013279,
0.059178426861763,
0.059794869273900986,
-0.04632120952010155,
-0.00737528782337904,
-0.003563805017620325,
0.04000268131494522,
-0.00974198430776596,
0.004645330365747213,
-0.0049122716300189495,
-0.02718949317932129,
-0.029831387102603912,
0.0... | 2025-01-23 | 63 | 39844819 | [
"target combinations",
"target",
"superior antitumor CAR effects",
"various cancer types",
"antigen escape",
"tumor cells",
"varying degrees",
"tumor models",
"different types",
"tumor",
"different dual-target CAR-T studies",
"dual-target CAR-T therapies",
"various preclinical and clinical s... | [
"cancer immunotherapy",
"dual-target CAR-T",
"hematological malignancies",
"solid tumors"
] | 0 | 10.1155/jimr/5845167
10.1073/pnas.90.2.720
10.1038/s41591-019-0564-6
10.1182/blood.2019001641
10.1182/blood-2017-02-769208
10.1038/s41591-019-0549-5
10.1016/j.ajodo.2021.06.028
10.1172/JCI85309
10.1056/NEJMoa1709866
10.1182/bloodadvances.2020003092
10.3389/fimmu.2019.02664
10.1016/j.annonc.2020.10.478
10.1182/blood.202... | [
"Zhang",
"Liu"
] | [
"School of Medicine, University of Tsinghua, Beijing, China.\nDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.",
"Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."
] | [
"39844819",
"31650176",
"28408462",
"36127190",
"27111235",
"29385370",
"33147337",
"33098993",
"33156925",
"29385376",
"26516065",
"26907630",
"29812997",
"30896447",
"27412889",
"33626253",
"24048066",
"30135176",
"22526592",
"31725148",
"31697824",
"33833386",
"2951523... | [] | 8.246161 | 4.160666 |
39844295 | 1 | Application of adoptive cell therapy in malignant melanoma. | Cutaneous melanoma is one of the most aggressive skin cancers originating from skin pigment cells. Patients with advanced melanoma suffer a poor prognosis and generally cannot benefit well from surgical resection and chemo/target therapy due to metastasis and drug resistance. Thus, adoptive cell therapy (ACT), employin... | [
-0.0025810925289988518,
0.042373497039079666,
0.051993075758218765,
0.05337037518620491,
-0.00657445564866066,
0.0006899950094521046,
-0.004960432182997465,
0.029482828453183174,
0.007505209185183048,
-0.003752604592591524,
0.02045505680143833,
-0.051993075758218765,
-0.030429722741246223,
... | 2025-01-23 | 112 | 39844295 | [
"chimeric antigen receptor",
"adoptive cell therapy",
"skin pigment cells",
"immune cells",
"T cell",
"engineered T-cell receptor T cells",
"advanced melanoma",
"malignant melanoma",
"Cutaneous melanoma",
"tumor",
"surgical resection",
"future prospects",
"specific tumor-recognizing receptor... | [
"Adoptive Cell Therapy",
"Chimeric Antigen Receptors (CARs)-T cell",
"Malignant Melanoma",
"Natural Killer (NK) Cells",
"T-cell Receptors",
"Tumor-infiltrating Lymphocytes"
] | 0 | 10.1186/s12967-025-06093-2
10.3322/caac.21492
10.3322/caac.21332
10.3322/caac.21352
10.3390/ijms242115881
10.1016/j.critrevonc.2020.103208
10.1016/S0140-6736(21)01206-X
10.1080/21645515.2021.1971015
10.1016/j.clinthera.2015.02.018
10.1056/NEJMoa1504030
10.1056/NEJMoa1910836
10.1186/s13578-023-01073-9
10.1146/annurev-im... | [
"Hu",
"Xuan",
"Wang",
"Shen",
"Gao",
"Zhou",
"Wei",
"Gu"
] | [
"Department of Plastic and Reconstructive Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.",
"Department of Plastic and Reconstructive Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.",
"D... | [
"39844295",
"30207593",
"26742998",
"27232110",
"37958863",
"33383207",
"34509219",
"34882516",
"25823918",
"26027431",
"31562797",
"37386520",
"35471840",
"34441278",
"24670642",
"24853952",
"27232329",
"22439926",
"28187290",
"27951441",
"34743069",
"30470934",
"9619397... | [] | 10.290885 | 4.705851 |
39844281 | 2 | Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma. | Chimeric antigen receptor (CAR) T-cell therapy plays a critical role in the treatment of B-cell hematologic malignancies. The combination of PD-1 inhibitors and CAR-T has shown encouraging results in treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, there are still cases w... | [
0.006582936272025108,
-0.010425412096083164,
0.025771990418434143,
0.05952047184109688,
0.010011427104473114,
-0.0325123593211174,
0.0029110105242580175,
0.017853809520602226,
-0.013947195373475552,
0.003810406429693103,
-0.00629722885787487,
0.011200903914868832,
-0.05317659676074982,
0.0... | 2025-01-23 | 20 | 39844281 | [
"IL4I1 levels",
"IL4I1",
"DLBCL patients",
"R/R DLBCL patients",
"DLBCL treatment",
"Pfeiffer cells",
"R/R DLBCL",
"tumor tissue",
"combination therapy",
"Correlation analysis",
"CD19 CAR-T",
"Kyn",
"CD19 CAR-T. Therefore",
"poor prognosis",
"CAR-T cells",
"potential mechanisms",
"pa... | [
"CD19 CAR-T",
"DLBCL",
"IL4I1",
"Metabolism",
"PD-1 inhibitor"
] | 0 | 10.1186/s12967-024-06028-3
10.1056/NEJMoa011795
10.1016/j.blre.2023.101140
10.1056/NEJMoa1804980
10.1158/2643-3230.BCD-23-0056
10.1182/bloodadvances.2020003844
10.1136/jitc-2020-001466
10.1182/blood-2016-09-738245
10.1016/j.cell.2018.09.007
10.1158/1078-0432.CCR-20-1457
10.1016/j.tranon.2021.101085
10.3389/fonc.2019.00... | [
"Zhang",
"Zhang",
"Xiao",
"Liu",
"Zhao"
] | [
"Department of Hematology, Tianjin First Central Hospital, Tianjin, China.",
"Department of Hematology, First Center Clinic College of Tianjin Medical University, Tianjin, China.",
"Boyalife wsn ltd, Shen Zhen, China.",
"Boyalife wsn ltd, Shen Zhen, China. liuqingxi66@aliyun.com.",
"Department of Hematology... | [
"39844281",
"11807147",
"30501490",
"33414262",
"28031179",
"30290143",
"33028589",
"31482064",
"36275688",
"32818467",
"26885856",
"26850336",
"35704993",
"36045296",
"34113569",
"26813675",
"30290143",
"36779699",
"33828302",
"32217098"
] | [] | 7.412257 | 5.586925 |
39843688 | 3 | Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms. | Treatment for neuroendocrine neoplasms (NENs) is tailored to the tumor's site of origin, grade, and differentiation. NENs are categorized into two main types: well-differentiated neuroendocrine tumors (NETs), which tend to grow more slowly and are less aggressive, and poorly differentiated neuroendocrine carcinomas (NE... | [
-0.005444354843348265,
-0.00921536237001419,
0.05976240336894989,
0.04035157337784767,
-0.002009510761126876,
0.02543487958610058,
0.029546532779932022,
0.03540324792265892,
0.003908460959792137,
0.024024486541748047,
0.01702033169567585,
-0.021442750468850136,
-0.00969346147030592,
0.0119... | 2025-01-23 | 60 | 39843688 | [
"cancer cells",
"small cell lung cancer",
"immune checkpoint inhibitors",
"new therapies",
"other cancers",
"chimeric antigen receptor T cells",
"receptor radionuclide therapy",
"bispecific T cell engagers",
"immune attack",
"NENs",
"cancer vaccines",
"new hope",
"other therapeutic agents",
... | [
"Gastroenteropancreatic neuroendocrine cancers",
"Immune checkpoint inhibitors",
"Immunotherapy",
"Neuroendocrine carcinoma",
"Neuroendocrine tumor"
] | 0 | 10.1007/s11864-024-01283-4
10.1007/s00428-006-0250-1
10.1007/s00428-007-0452-1
10.1093/annonc/mds276
10.1111/cas.12473
10.1111/jne.13249
10.1056/NEJMoa1809064
10.1016/S0140-6736(19)32222-6
10.7150/jca.13711
10.1002/cncr.32883
10.1530/ERC-20-0382
10.1158/1078-0432.CCR-19-3014
10.1158/1078-0432.CCR-19-3356
10.1002/cncr.3... | [
"Urman",
"Schonman",
"De Jesus-Acosta"
] | [
"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.",
"Johns Hopkins Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.",
"The Sidney Kimmel Comprehensive ... | [
"39843688",
"16967267",
"17674042",
"22967994",
"24975505",
"36924180",
"30280641",
"31590988",
"26958083",
"32320048",
"33480358",
"31980466",
"31969335",
"33882143",
"37221181",
"39117670",
"32532787",
"32203769",
"33428585",
"25991820",
"34568063",
"33409812",
"3598395... | [] | 11.116188 | 5.0375 |
39841845 | 4 | Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. | A major limiting factor in the success of chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors is targeting tumor antigens also found on normal tissues. CAR T cells against GD2 induced rapid, fatal neurotoxicity because of CAR recognition of GD2 | [
0.03570399805903435,
0.02385634556412697,
0.057282835245132446,
0.07232820242643356,
-0.03846461698412895,
-0.04488305747509003,
0.012629829347133636,
0.004790823440998793,
-0.02995271049439907,
-0.005112895742058754,
-0.020934689790010452,
-0.011813146993517876,
-0.035934049636125565,
0.0... | 2025-01-22 | 1 | 39841845 | [
"CAR T cells",
"tumor antigens",
"T cell therapy",
"chimeric antigen receptor",
"solid tumors",
"CAR recognition",
"GD2",
"normal tissues",
"CAR",
"rapid, fatal neurotoxicity",
"A major limiting factor",
"the success",
"the treatment"
] | [] | 0 | 10.1126/sciadv.ads3403 | [
"Vogt",
"Silberman",
"Lin",
"Han",
"Laflin",
"Gellineau",
"Heller",
"Scheinberg"
] | [
"Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.\nGraduate School of Medical Sciences, Weill Cornell Medicine, New York, NY 10065, USA.\nTri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.",
"Molecular... | [
"39841845"
] | [] | 9.616429 | 6.79694 |
39841806 | 5 | Triple knockdown of | "Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the landscape of cancer treatm(...TRUNCATED) | [0.013676300644874573,0.025339338928461075,0.047948043793439865,0.07261629402637482,-0.0426719076931(...TRUNCATED) | 2025-01-22 | 1 | 39841806 | ["CAR)-T cell therapies","solid tumors","tumor","Chimeric antigen receptor","improved CAR-T cell the(...TRUNCATED) | [] | 0 | 10.1126/scitranslmed.adl6432 | ["Wang","Wu","Cui","Bian","Zheng","Zhu","Geng","Sun","Pan","Shi","Yi","Song","Li","Shen","Li","Shen"(...TRUNCATED) | ["Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Med(...TRUNCATED) | [
"39841806"
] | [] | 8.998252 | 5.280612 |
39840882 | 6 | [Patient with diffuse large B-cell lymphoma: a good example of network in care.]. | "Chimeric Antigen Receptor T cell (CAR-T) therapy has revolutionized prognosis of patients with diff(...TRUNCATED) | [0.018854942172765732,0.02260638028383255,0.052886709570884705,0.06867451965808868,-0.02425603568553(...TRUNCATED) | 2025-01-22 | 1 | 39840882 | ["marginal zone lymphoma","holding therapy","early referral","complete remission","diffuse large B-c(...TRUNCATED) | [] | 0 | 10.1701/4416.44128 | [
"Tisi"
] | [
"UO Ematologia, Ospedale San Bortolo, Vicenza."
] | [
"39840882"
] | [] | 6.266233 | 5.473475 |
39839908 | 7 | "A bioluminescent reporter bioassay for in-process assessment of chimeric antigen receptor lentivira(...TRUNCATED) | "Chimeric antigen receptor (CAR)-T-cell therapy is a breakthrough in the field of cancer immunothera(...TRUNCATED) | [-0.0014690025709569454,-0.01320493035018444,-0.009483763948082924,0.024350037798285484,-0.019641874(...TRUNCATED) | 2025-01-22 | 22 | 39839908 | ["CAR LV","LV potency","LV MOA","LV quantification","T cells","activated T cells","patient T cells",(...TRUNCATED) | [
"CAR-T",
"bioassay",
"lentivirus",
"potency assay"
] | 0 | "10.1093/abt/tbae032\n10.1016/j.ebiom.2020.102931\n10.1038/nbt0102-70\n10.4049/jimmunol.172.1.104\n1(...TRUNCATED) | [
"Gilden",
"Stecha",
"Hartnett",
"Cong"
] | ["Research and Development, Promega Corp., Madison, WI 53711, United States.","Research and Developm(...TRUNCATED) | ["39839908","32739874","11753365","14688315","20683006","37215709","36253252","16836756","38282894",(...TRUNCATED) | [] | 8.165737 | 4.711771 |
39837618 | 8 | Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment. | "In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment (...TRUNCATED) | [-0.029780112206935883,0.007054430432617664,0.02348320372402668,0.03451462835073471,-0.0084570311009(...TRUNCATED) | 2025-01-22 | 61 | 39837618 | ["TIL immunotherapy","TIL manufacturing","TIL","clinical practice guidelines","underlying clinical r(...TRUNCATED) | ["Adoptive cell therapy - ACT","Cytokine","Immunotherapy","Surgery","Tumor infiltrating lymphocyte -(...TRUNCATED) | 0 | "10.1136/jitc-2024-010207\n10.1126/science.aad1253\n10.1172/JCI82416\n10.1016/j.ccell.2023.11.005\n1(...TRUNCATED) | ["Turcotte","Donia","Gastman","Besser","Brown","Coukos","Creelan","Mullinax","Sondak","Yang","Rohaan(...TRUNCATED) | ["Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.","Department of Oncol(...TRUNCATED) | ["39837618","26516200","26389673","38039963","37820582","3489291","3264384","12242449","34413159","3(...TRUNCATED) | [] | 10.194453 | 4.454338 |
39836430 | 9 | "Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antig(...TRUNCATED) | "Orvacabtagene autoleucel (orva-cel; JCARH125), a CAR T-cell therapy targeting B-cell maturation ant(...TRUNCATED) | [0.03012278489768505,0.003520004218444228,0.03740132227540016,0.01596098765730858,-0.070713579654693(...TRUNCATED) | 2025-01-21 | 1 | 39836430 | ["CAR+ T cells","T cell biology","Traditional piecewise models","plasma cells","traditional models",(...TRUNCATED) | [] | 0 | 10.1158/1078-0432.CCR-24-2753 | [
"Hu",
"Li",
"Piasecki",
"Hosseyni",
"Yan",
"Liu",
"Ogasawara",
"Zhou",
"Cheng"
] | ["Bristol-Myers Squibb (United States), Princeton, New Jersey, United States.","Bristol-Myers Squibb(...TRUNCATED) | [
"39836430"
] | [] | 5.44703 | 5.483919 |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 6